AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04206943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Car-T Cell Therapy
Description: Lymphodepletion Protocol:~* -6. Day: Cyclophosphamide 300 mg / m\^2 i.v.~* -5. -4. and -3. Days: Fludarabine 30 mg / m\^2 i.v. In addition, one day before the lymphodepletion protocol, xanthine oxidase enzyme inhibitor tablets received 100 mg / day p.o. and 0.9% sodium chloride solution 2000 ml / day i.v. infusion on protocol day received and continues for 2 weeks~Car-T cells are administered in 3 split doses. Day 0: 20% or 40% (20% in patients with high tumor burden - in patients with bulky disease and / or more than 15% blast in bone marrow, 40% in patients with low tumor burden) Day 2: 30% or 50%, (the total amount of Car-T cell dose that should be given in the first 2 days should be 70%.) Third dose (%30);is given on the 7th day in the absence of cytokine release syndrome, or if cytokine release syndrome occurs, Car-T cells are given within 1 month if the number of copies falls below 5,000 / ml in 2 consecutive measurements.
Study NCT03652428 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: see arm description
Study NCT03652428 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Hypofractionated Ablative Proton Therapy
Description: see arm description
Study NCT01740518 — intervention group
Intervention type: DRUG
Intervention: polyethylene glycol, ascorbic acid
Description: comparison of different solutions for bowel preparation
Study NCT01251744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urine sampling
Description: Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
Study NCT01251744 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vaginal swab
Description: Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
Study NCT01670604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)
Study NCT01670604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetraspan, B. Braun, Melsungen, Germany
Study NCT01264016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Blood Glucose Monitoring System
Description: Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
Study NCT03376906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIIE 1
Description: In the HIIE 1 session, all the subjects performed 10 stimuli of 1 min at high intensity (92% of VO2Max) with passive recovery (without exercise) of 1 min.
Study NCT03376906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIIE 3
Description: In the HIIE 3 session, the subjects performed the same stimulus of the HIIE1, but with passive recovery of 3 min. Both protocols started with a warm-up of 5 min at 50% of the VO2Peak performed on a T2-100 GE Healthcare® treadmill (Lynn Medical, Wixon, Michigan, USA).
Study NCT03376906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Control
Description: In the control session, participants remained seated for 30 min. During HIIE 1 and 2, HR and RPE were assessed immediately after stimulus intervals (ten measurements at each HIIE). In all sessions, the subjects remained in supine position to obtain hemodynamic measurements which were obtained before and at 10 min, 30 min and 60 min after the HIIE and control sessions.
Study NCT00121264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT03433274 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MitraClip System
Description: Percutaneous mitral valve repair using the MitraClip system.
Study NCT02913196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.~Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD
Study NCT02913196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.~Dose: 1000 mg QD
Study NCT02913196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.~Dose: 75 mg/m2 Q3W
Study NCT02913196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Dose: 5 mg BID
Study NCT00121264 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tanespimycin
Description: Given IV
Study NCT00121264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00121264 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00121264 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Correlative studies
Study NCT00857402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Peanuts
Description: 30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
Study NCT00857402 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Daboqolo
Description: 30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
Study NCT04686123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Stretching or Self-stretching exercises
Description: Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
Study NCT04686123 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Stretching or Self-stretching exercises
Description: Pectoralis minor muscle was actively stretched under the supervision of a physiotherapist as follows: - 2 sets of 3-stretches/session/day, for 5 consecutive days a week, for 3 weeks
Study NCT04686123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active strengthening Or Self-Strengthening exercises
Description: Lower trapezius muscle was strengthened under the supervision of a physiotherapist as follows: -2 sets of 5-rep./session/day, for 5 consecutive days in 1st week, progressed to 10 and 20 reps./session/day for 2 weeks and 3 weeks respectively.
Study NCT00365144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00365144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Study NCT00365144 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00116168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 0.3 mg/kg
Description: MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
Study NCT00116168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 1 mg/kg
Description: MEDI-528 (1 mg/kg) administered as a single, SC dose
Study NCT00116168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 3 mg/kg
Description: MEDI-528 (3 mg/kg) administered as a single, SC dose
Study NCT00116168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI-528 9 mg/kg
Description: MEDI-528 (9 mg/kg) administered as a single, SC dose
Study NCT01545453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lebrikizumab
Description: subcutaneous dose every 4 weeks
Study NCT02980900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise protein-polyphenol supplement
Description: Participants will ingest a post exercise protein-polyphenol supplement. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study NCT02980900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Post exercise placebo supplement
Description: Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study NCT02319057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediate release formulation of ORM-12741
Study NCT02319057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741
Study NCT04624594 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence Feedback
Description: AI mobile application provides feedback to participants randomized to artificial intelligence group.
Study NCT04624594 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapist Feedback
Description: PT provides feedback to participants randomized to physical therapist group.
Study NCT00006124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Given orally
Study NCT00006124 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT02254109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR - rising dose
Study NCT02254109 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04072003 — intervention group
Intervention type: DEVICE
Intervention: intravascular ultrasound (IVUS)
Description: use IVUS in the procedure
Study NCT04072003 — intervention group
Intervention type: OTHER
Intervention: coronary angiography
Description: Coronary angiography is required for all PCI procedure.
Study NCT01566851 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular check-up
Description: Cardiovascular check-up once a year in patients with rheumatoid arthritis
Study NCT00593827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m\^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
Study NCT00593827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ixabepilone
Description: Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m\^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
Study NCT04302935 — intervention group
Intervention type: OTHER
Intervention: Global pain-assessment
Description: Global pain-assessment, based on the ICF framework
Study NCT04254809 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Re-Evaluating Suicidal Thoughts
Description: Re-Evaluating Suicidal Thoughts (REST) is a is a computerized intervention designed to mitigate the experiential avoidance of suicidal thoughts. Over the course of approximately 30 minutes, individuals are provided with psychoeducation regarding the incidence rate, origin, conceptualization, and misconceptions of suicidal thoughts. Empirical evidence is presented to provide a scientific understanding of suicidal thoughts, and is aided through the use of metaphors to make concepts more accessible to viewers. REST draws from therapeutic strategies rooted in cognitive behavioral therapy (CBT) and Acceptance and Commitment Therapy (ACT) to further suggest tips for accepting (cp. approving of) the occurrence of suicidal thoughts, and introduces mindfulness and acceptance strategies for coping with them.
Study NCT02980900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post exercise placebo supplement
Description: Participants will ingest an isocaloric placebo supplement after exercise. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study NCT02980900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre bed protein-polyphenol supplement
Description: Participants will ingest a protein-polyphenol supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study NCT02980900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pre bed placebo supplement
Description: Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study NCT02980900 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Pre bed placebo supplement
Description: Participants will ingest an isocaloric placebo supplement before bed. This will begin 6 days before eccentric exercise and will end 6 days after eccentric exercise.
Study NCT02579057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide Injection Solution (SCP-101)
Study NCT02579057 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide Injection Solution, USP
Study NCT03373669 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Cholera Vaccine
Description: Shanchol is a bivalent (O1 and O139 serotypes) vaccine using a heat-killed classical Inaba strain and a formalin-killed classical Ogawa strain produced by Sanofi. Shanchol requires no oral buffer for administration, is approved for persons greater than 1 year of age, and requires 2 doses at two-week intervals. It became World Health Organization (WHO) prequalified in 2011.
Study NCT03373669 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjusted Dose Oral Cholera Vaccine
Description: The Adjusted Dose Oral Cholera Vaccine is given in two doses, with the second dose given at six months, rather than the manufacturer described 2 week interval between first and second dose.
Study NCT02624687 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: Participants participated in monthly, individual counselling with a trained interventionist to decrease sedentary behavior and improve pain self-management. Participants were provided with a sit-stand desk attachment and a wrist worn activity prompter..
Study NCT02624687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No intervention
Description: No contact control
Study NCT04642209 — intervention group
Intervention type: DEVICE
Intervention: Aggregometry
Description: After evaluation at the Emergency Department the anesthesiologist immediately collects a sample of blood for TEG with ADP Platelet Mapping test.~If both MA-ADP and platelets aggregation (%) are within normal values (i.e. ≥45 mm and ≥83%, respectively), the patient could be considered as candidate for immediate surgery (within 48 hours) with neuraxial anesthesia.~If MA-ADP and/or platelets aggregation (%) are lower than normal values, the Nottingham Hip Fracture Score (NHFS) is computed, to predict the 30-day mortality after hip fracture surgery. If NHFS is ≥4 (high risk), the patient will undergo to general anesthesia and peripheral antalgic block, to perform surgery within 48 hours. In case of low risk for mortality (i.e. a NHFS \<4), surgery will be postponed until the normalization of both MA-ADP and platelet aggregation.
Study NCT04072939 — intervention group
Intervention type: OTHER
Intervention: Patients having had a lens surgery
Description: Dilated fundus exam
Study NCT00552279 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix TM
Description: Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
Study NCT00552279 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervarix TM
Description: Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
Study NCT04211948 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robotic surgery
Description: Pancreatectomy with robotic assisted system
Study NCT04211948 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: Traditional open pancreatectomy
Study NCT01545453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: subcutaneous dose every 4 weeks
Study NCT02169973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42165279
Description: Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
Study NCT02169973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-MK-3168
Description: Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
Study NCT02138422 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xilonix
Study NCT02138422 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02758756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Massage
Description: Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
Study NCT02758756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki
Description: Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
Study NCT03543618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sloped
Description: Placement of implant with sloped design
Study NCT03543618 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Placement of implant with conventional design
Study NCT02593201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended antibiotics (cefazolin or ceftazidime)
Description: To continue with the existing effective antibiotic therapy for one extra week
Study NCT02593201 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Usual antibiotics (cefazolin or ceftazidime)
Description: Usual duration of effective antibiotic therapy therapy
Study NCT01200849 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Label
Description: A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
Study NCT01632137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide 2% ophthalmic suspension
Description: Instill one drop into each eye 4 times a day for 4 weeks.
Study NCT01632137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (vehicle)
Description: Instill one drop into each eye 4 times a day for 4 weeks.
Study NCT02824965 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
Study NCT02824965 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVA21
Description: CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
Study NCT00557427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hypericum
Description: 250mg tablets twice daily for 8 weeks
Study NCT00557427 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20mg - 40mg daily for 8 weeks
Study NCT04019431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein, vegetable protein or animal protein
Description: meal replacements or animal protein
Study NCT04019431 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein, vegetable protein or animal protein
Description: meal replacements or animal protein
Study NCT01129674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Description: Administered orally, twice daily for 104 weeks
Study NCT01129674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks